WCG Executive and Leadership Team

Sam Srivastava, the Chief Executive Officer at WCG, directs the overarching strategy and vision for the organization. Srivastava guides WCG's mission to measurably improve the quality and efficiency of clinical trials, ensuring new treatments and therapies reach patients faster. This leadership role involves aligning all departments toward achieving WCG's core objectives and expanding its market impact within the biopharmaceutical and institutional sectors. Srivastava's strategic direction ensures WCG remains at the forefront of clinical trial facilitation, driving innovation and operational excellence across the company. The Chief Executive Officer's focus is on sustainable growth and enhancing WCG's reputation as a leader in the industry. By fostering a culture of collaboration and accountability, Srivastava empowers teams to deliver exceptional results. This executive's oversight extends to all facets of the business, ensuring seamless integration of services and client satisfaction. Sam Srivastava's leadership is pivotal in navigating the complex landscape of clinical research and development.

Todd Joron, the Co-Founder & Wcg Imaging President & Chief Operating Officer at WCG, spearheads operational execution and oversees the strategic direction of WCG Imaging. Joron's dual role ensures the seamless integration of imaging services into broader clinical trial processes, enhancing data quality and trial efficiency. This leadership position involves managing day-to-day operations across multiple departments, driving productivity, and optimizing resource allocation. The Co-Founder & Wcg Imaging President & Chief Operating Officer is instrumental in scaling WCG's capabilities to meet the growing demands of the biopharmaceutical industry. Joron's focus is on operational excellence, ensuring that WCG Imaging delivers reliable and high-quality services that accelerate the development of new therapies. Todd Joron's commitment to innovation and efficiency is key to WCG's success in facilitating clinical trials. This executive's oversight guarantees that WCG Imaging remains a critical component of WCG's comprehensive service offering, supporting patient treatment advancements.

Cynthia Carter, the President, MI & I at WCG, directs the strategic initiatives and operational performance for the MI & I division. Carter is focused on enhancing the quality and efficiency of clinical trials through specialized services within this segment. This leadership position involves overseeing the integration of MI & I solutions to support biopharmaceutical companies and institutions in developing new treatments. The President, MI & I ensures that this division contributes significantly to WCG's overall mission of accelerating patient therapy development. Carter's expertise drives innovation and operational excellence within her area of responsibility. Cynthia Carter's leadership is key to maximizing the impact of MI & I services, reinforcing WCG's position as a leader in clinical research. This executive's focus is on delivering measurable improvements and supporting the advancement of medical science.

Robert VanHees, the President, Chief Financial & Chief Administrative Officer at WCG, oversees the financial health and administrative operations of the organization. VanHees ensures robust financial planning, management, and reporting to support WCG's mission of improving clinical trial quality and efficiency. This executive role involves managing fiscal resources effectively to facilitate the development of new treatments and therapies for patients. The President, Chief Financial & Chief Administrative Officer is responsible for optimizing administrative functions to enhance operational performance and support strategic growth initiatives. VanHees's financial acumen and administrative oversight are critical for WCG's sustained success and market leadership. Robert VanHees's leadership ensures financial stability and operational efficiency, enabling WCG to effectively serve its clients. This executive's focus is on prudent financial management and streamlined administrative processes.

Theresa Moench, the President, Clinical Research Solutions at WCG, leads the strategic direction and operational execution of WCG's comprehensive clinical research services. Moench is dedicated to enhancing the quality and efficiency of clinical trials, directly supporting biopharmaceutical companies and institutions in their efforts to develop new treatments. This critical role involves overseeing a broad spectrum of services designed to accelerate patient therapy development and ensure regulatory compliance. The President, Clinical Research Solutions drives innovation within service delivery, optimizing processes to meet the evolving needs of the industry. Moench's leadership ensures that WCG provides cutting-edge solutions that improve patient outcomes and streamline research timelines. Theresa Moench's commitment to excellence is fundamental to WCG's mission of advancing medical science. This executive's focus is on delivering integrated solutions that facilitate groundbreaking research and bring life-changing therapies to market.

Rbih Mansur, the President at WCG, directs key strategic initiatives and operational functions within the organization. Mansur focuses on advancing WCG's mission to measurably improve the quality and efficiency of clinical trials, thereby accelerating the development of new treatments and therapies. This leadership position involves overseeing critical business areas to ensure seamless execution and client satisfaction. The President is responsible for driving operational excellence and fostering an environment conducive to innovation and growth. Mansur's strategic oversight contributes significantly to WCG's ability to support biopharmaceutical companies and institutions effectively. Rbih Mansur's leadership ensures that WCG remains a trusted partner in clinical research, committed to patient well-being. This executive's efforts are vital in navigating the complexities of the healthcare industry and achieving WCG's overarching goals.

Paul Mancinelli, the Chief Technology Officer at WCG, architects the technological infrastructure and digital strategy that underpins WCG's operations. Mancinelli drives the innovation of platforms and systems designed to enhance the quality and efficiency of clinical trials. This role involves overseeing the development and implementation of cutting-edge solutions that support biopharmaceutical companies, CROs, and institutions in their pursuit of new treatments. The Chief Technology Officer ensures WCG's technological capabilities provide a competitive advantage, enabling faster drug development cycles. Mancinelli's expertise is critical in managing data integrity, security, and scalability across all WCG's digital assets. By championing technological advancements, Paul Mancinelli empowers WCG to deliver superior services and maintain its leadership position. This executive's vision shapes the future of clinical trial technology, optimizing processes and improving patient outcomes. The Chief Technology Officer's responsibilities include evaluating emerging technologies and integrating them to further WCG's mission.

Antonio Castillo, the Director, Chief Revenue Officer Partnerships at WCG, drives revenue growth through strategic partnerships and client relationship management. Castillo focuses on expanding WCG's market reach by forging strong alliances with biopharmaceutical companies, CROs, and research institutions. This role involves identifying new business opportunities and ensuring WCG's services effectively support the development of new treatments and therapies. The Director, Chief Revenue Officer Partnerships is responsible for cultivating and nurturing key relationships that contribute to WCG's sustained success and operational efficiency. Castillo's expertise in revenue generation and partnership development is crucial for WCG's continued expansion. By fostering collaborative ventures, Antonio Castillo enhances WCG's ability to facilitate clinical trials and bring innovative therapies to patients. This executive's strategic approach to partnerships directly impacts WCG's market position and overall growth trajectory.

Elisa Calicchio, the Senior Vice President and Chief Human Resources Officer at WCG, leads the human capital strategy to support WCG's mission of improving clinical trial quality and efficiency. Calicchio focuses on attracting, developing, and retaining top talent essential for facilitating the development of new treatments and therapies. This executive role involves shaping the organizational culture, ensuring employee engagement, and implementing HR policies that align with WCG's strategic objectives. The Senior Vice President and Chief Human Resources Officer plays a vital part in fostering a high-performance environment that drives innovation and operational excellence. Calicchio's leadership ensures WCG has the skilled workforce necessary to meet the complex demands of the biopharmaceutical industry. Elisa Calicchio's dedication to human resources excellence supports WCG's ability to deliver exceptional services to clients and advance patient care. This executive's efforts are critical in building a robust and motivated team.